TY - JOUR
T1 - Protective effects of Indian spice curcumin against Amyloid-ß in Alzheimer's disease
AU - Reddy, P. Hemachandra
AU - Manczak, Maria
AU - Yin, Xiangling
AU - Grady, Mary Catherine
AU - Mitchell, Andrew
AU - Tonk, Sahil
AU - Kuruva, Chandra Sekhar
AU - Bhatti, Jasvinder Singh
AU - Kandimalla, Ramesh
AU - Vijayan, Murali
AU - Kumar, Subodh
AU - Wang, Rui
AU - Pradeepkiran, Jangampalli Adi
AU - Ogunmokun, Gilbert
AU - Thamarai, Kavya
AU - Quesada, Kandi
AU - Boles, Annette
AU - Reddy, Arubala P.
N1 - Publisher Copyright:
© 2018 - IOS Press and the authors.
PY - 2018
Y1 - 2018
N2 - The purpose of our article is to assess the current understanding of Indian spice, curcumin, against amyloid-ß (Aß)-induced toxicity in Alzheimer's disease (AD) pathogenesis. Natural products, such as ginger, curcumin, and gingko biloba have been used as diets and dietary supplements to treat human diseases, including cancer, cardiovascular, respiratory, infectious, diabetes, obesity, metabolic syndromes, and neurological disorders. Products derived from plants are known to have protective effects, including anti-inflammatory, antioxidant, anti-arthritis, pro-healing, and boosting memory cognitive functions. In the last decade, several groups have designed and synthesized curcumin and its derivatives and extensively tested using cell and mouse models of AD. Recent research on Aß and curcumin has revealed that curcumin prevents Aß aggregation and crosses the blood-brain barrier, reach brain cells, and protect neurons from various toxic insults of aging and Aß in humans. Recent research has also reported that curcumin ameliorates cognitive decline and improves synaptic functions in mouse models of AD. Further, recent groups have initiated studies on elderly individuals and patients with AD and the outcome of these studies is currently being assessed. This article highlights the beneficial effects of curcumin on AD. This article also critically assesses the current limitations of curcumin's bioavailability and urgent need for new formulations to increase its brain levels to treat patients with AD.
AB - The purpose of our article is to assess the current understanding of Indian spice, curcumin, against amyloid-ß (Aß)-induced toxicity in Alzheimer's disease (AD) pathogenesis. Natural products, such as ginger, curcumin, and gingko biloba have been used as diets and dietary supplements to treat human diseases, including cancer, cardiovascular, respiratory, infectious, diabetes, obesity, metabolic syndromes, and neurological disorders. Products derived from plants are known to have protective effects, including anti-inflammatory, antioxidant, anti-arthritis, pro-healing, and boosting memory cognitive functions. In the last decade, several groups have designed and synthesized curcumin and its derivatives and extensively tested using cell and mouse models of AD. Recent research on Aß and curcumin has revealed that curcumin prevents Aß aggregation and crosses the blood-brain barrier, reach brain cells, and protect neurons from various toxic insults of aging and Aß in humans. Recent research has also reported that curcumin ameliorates cognitive decline and improves synaptic functions in mouse models of AD. Further, recent groups have initiated studies on elderly individuals and patients with AD and the outcome of these studies is currently being assessed. This article highlights the beneficial effects of curcumin on AD. This article also critically assesses the current limitations of curcumin's bioavailability and urgent need for new formulations to increase its brain levels to treat patients with AD.
KW - Alzheimer's disease
KW - Amyloid-ß
KW - Amyloid-ß protein precursor
KW - Curcumin
KW - Mitochondria
KW - Oxidative stress
KW - Reactive oxygen species
UR - http://www.scopus.com/inward/record.url?scp=85044773243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044773243&partnerID=8YFLogxK
U2 - 10.3233/JAD-170512
DO - 10.3233/JAD-170512
M3 - Review article
C2 - 29332042
AN - SCOPUS:85044773243
SN - 1387-2877
VL - 61
SP - 843
EP - 866
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 3
ER -